Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 80Breast 42Thoracic 24Genitourinary 19Sarcoma 13Head & Neck 11Gynecologic 11CNS 6Lymphoid 5Tumor-Agnostic 3Plasma cell 3Other solid neoplasm 2Endocrine 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoadjuvant Therapy × Tumor-Agnostic × Clear all
NCT06417190 2026-05-04

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Cedars-Sinai Medical Center

Phase 2 Recruiting
20 enrolled
Tumor-Agnostic

Neoplasms

NCT06831136 2025-09-10

PANCARDINAL-2

The University of Texas Health Science Center, Houston

Phase 2 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03406650 2025-05-04

SAKK 06/17

Swiss Cancer Institute

Phase 2 Completed
61 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡